Investors
Roche’s Virtual Immunology/SLEuro Investor Event
Roche has hosted a virtual event on Monday, 9 March 2026
:quality(90)/)
Roche’s Virtual Neurology/ACTRIMS Investor Event
Roche has hosted a virtual event on Monday, 9 February 2026
Investors at a glance
+11%
Core earnings per share growth at Constant Exchange Rates in 2025 (Core EPS 19.46 CHF - diluted)
39 million
patients were treated with Roche medicines in 2025
31 billion
Roche Diagnostic tests were delivered to customers worldwide in 2025
Our two divisions are focusing jointly on three disease areas that will account for almost 50% of the global disease burden by 2035: cancer, cardiovascular-metabolic diseases and neurological diseases.
:quality(90)/)
Investor updates
Upcoming Investor events
View all eventsLatest reports
:quality(90)/)
:quality(90)/)
Investor relations team contacts
Do you need to get in touch with us? Reach out to our investor relations team with your enquiries.